Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Celldex Therapeutics, Inc., Charles River Laboratories International and Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Latest Biotechnology and Celldex Therapeutics, Inc., Charles River Laboratories International, Inc. Stock News

As of July 30, 2026, Celldex Therapeutics, Inc. had a $3.0 billion market capitalization, compared to the Biotechnology median of $251.9 million. Celldex Therapeutics, Inc.’s stock is up 40.1% in 2026, up 7.9% in the previous five trading days and up 75.33% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $0.9 million with a % net profit margin. As of July 30, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.352 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

As of July 30, 2026, Charles River Laboratories International, Inc. had a $11.3 billion market cap, putting it in the 79th percentile of all stocks. Charles River Laboratories International, Inc.’s stock is up 16.6% in 2026, up 2.6% in the previous five trading days and up 31.48% in the past year.

Currently, Charles River Laboratories International, Inc. does not have a price-earnings ratio. Charles River Laboratories International, Inc.’s trailing 12-month revenue is $4.0 billion with a -4.6% net profit margin. Year-over-year quarterly sales growth most recently was 1.2%. Analysts expect adjusted earnings to reach $11.106 per share for the current fiscal year. Charles River Laboratories International, Inc. does not currently pay a dividend.

How We Compare Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Celldex Therapeutics, Inc., Charles River Laboratories International and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. Stock Value Grades

Company	Ticker	Value
Celldex Therapeutics, Inc.	CLDX	na
Charles River Laboratories International, Inc.	CRL	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Celldex Therapeutics, Inc. does not have a meaningful Value Score. Charles River Laboratories International, Inc. has a Value Score of 32, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. is the better investment when it comes to value.

Celldex Therapeutics, Inc., Charles River Laboratories International and Inc.’s Momentum Grades

Company	Ticker	Momentum
Celldex Therapeutics, Inc.	CLDX	A
Charles River Laboratories International, Inc.	CRL	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Celldex Therapeutics, Inc. has a Momentum Score of 83, which is Very Strong. Charles River Laboratories International, Inc. has a Momentum Score of 84, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Celldex Therapeutics, Inc., Charles River Laboratories International and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Celldex Therapeutics, Inc.	CLDX	C
Charles River Laboratories International, Inc.	CRL	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Celldex Therapeutics, Inc. has a Earnings Estimate Score of 47, which is Neutral. Charles River Laboratories International, Inc. has a Earnings Estimate Score of 54, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. is the better investment when it comes to estimate revisions.

Other Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. Grades

In addition to Value, Estimate Revisions and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Celldex Therapeutics, Inc., Charles River Laboratories International and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Celldex Therapeutics, Inc., Charles River Laboratories International or Inc. Stock?

Overall, Celldex Therapeutics, Inc. stock has a Value Score of , Momentum Score of 83 and Estimate Revisions Score of 47.

Charles River Laboratories International, Inc. stock has a Value Score of 32, Momentum Score of 84 and Estimate Revisions Score of 54.

Comparing Celldex Therapeutics, Inc., Charles River Laboratories International and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.